Business · 03/08/2006Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for CYMBALTA Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of CYMBALTA, a human drug product, in accordance with federal regulations.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →